Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TPST-1120 · 1 trial · 1 indication
Overall survival (OS), defined as the time from randomization to death from any cause up to 60 months.
| Arm | Type | Description |
|---|---|---|
| Active Arm | EXPERIMENTAL | TPST-1120 600 mg by mouth (PO) twice daily (BID) with atezolizumab 1200 mg intravenously (IV) every 3 weeks (Q3W) and bevacizumab 15 mg/kg IV Q3W |
| Control Arm | ACTIVE_COMPARATOR | Placebo tablets PO BID with atezolizumab 1200 mg IV Q3W and bevacizumab 15 mg/kg IV Q3W |
| Name | Type | Description |
|---|---|---|
| TPST-1120 | DRUG | TPST-1120 is an orally administered competitive antagonist of peroxisome proliferator-activated receptor α (PPARα) |
| Atezolizumab | BIOLOGICAL | Atezolizumab is an IV administered biologic. |
| Bevacizumab | BIOLOGICAL | Bevacizumab is an IV administered biologic. |
Inclusion Criteria: 1. Written informed consent 2. Age ≥ 18 years at the time of signing ICF 3. HCC diagnosis confirmed by histology/cytology or clinically by the American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients a) Patients without cirrhosis require hi...
TPST-1120 is an investigational small molecule being studied for the treatment of unresectable or metastatic Hepatocellular Carcinoma (HCC) in patients who have not previously received systemic therapy. It is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
TPST-1120 targets PPARα, a nuclear receptor involved in metabolic regulation. By modulating this target, the drug is being evaluated for its potential role in treating Hepatocellular Carcinoma. Its exact mechanism of action in this context is under investigation in clinical trials.
TPST-1120 is being developed by Tempest Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TPST. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Hepatocellular Carcinoma.
TPST-1120 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 3 trial is designed to assess its efficacy and safety in patients with previously untreated unresectable or metastatic Hepatocellular Carcinoma.
TPST-1120 is being studied in a Phase 3 clinical trial with the identifier NCT06680258. This randomized, double-blind, active-controlled study is evaluating TPST-1120 in combination with atezolizumab plus bevacizumab in patients with unresectable or metastatic Hepatocellular Carcinoma who have not received prior systemic therapy. The trial aims to enroll approximately 740 participants.